Herpes Zoster

Medical Clinics of North America

Volumn 97, Issue 4, 2013, Pages 503-522

  O'Connor, Kim M ^a   Paauw, Douglas S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Herpes zoster; Immunosuppression; Shingles; Varicella zoster virus

Indexed keywords

ACICLOVIR; ADALIMUMAB; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CAPSAICIN; CORTICOSTEROID; CYCLOSPORIN; DESIPRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FAMCICLOVIR; GABAPENTIN; GLUCOCORTICOID; INFLIXIMAB; LIDOCAINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NARCOTIC AGENT; NORTRIPTYLINE; OXYCODONE; PREDNISONE; PREGABALIN; STEROID; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ALLODYNIA; ASEPTIC MENINGITIS; BACTERIAL INFECTION; CELLULAR IMMUNITY; CELLULITIS; CEREBROVASCULAR ACCIDENT; CONFUSION; CONSTIPATION; DERMATOME; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIZZINESS; DNA VIRUS; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSESTHESIA; EDEMA; ENCEPHALITIS; FEVER; GAIT; GUILLAIN BARRE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INJECTION SITE REACTION; LATENT PERIOD; LONG TERM CARE; MALAISE; MYELITIS; NAUSEA; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PREGNANCY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; RASH; RESPIRATION DEPRESSION; RETINA DETACHMENT; RETINITIS; REVIEW; SOMNOLENCE; TRIGEMINAL NERVE; TRIGEMINUS GANGLION; URINE RETENTION; VACCINATION; VARICELLA ZOSTER VIRUS; VESICULAR RASH; VIRUS CULTURE; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REACTIVATION; XEROSTOMIA;

ANTIVIRAL AGENTS; CANADA; DIAGNOSIS, DIFFERENTIAL; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC; RISK FACTORS; UNITED STATES;

EID: 84879784540     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.02.002     Document Type: Review

References (82)

1. Gnann J.W., Whitley R.J. Clinical practice. Herpes zoster. NEngl J Med 2002, 347(5):340-346.
2. Harpaz R., Ortega-Sanchez I.R., Seward J.F., et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-5):1-30. [quiz: CE2-4].
3. Wareham D.W., Breuer J. Herpes zoster. BMJ 2007, 334(7605):1211-1215.
4. Drolet M., Brisson M., Schmader K.E., et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010, 182(16):1731-1736.
5. Yawn B.P., Itzler R.F., Wollan P.C., et al. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009, 84(9):787-794.
6. Hope-Simpson R.E. Postherpetic neuralgia. JR Coll Gen Pract 1975, 25(157):571-575.
7. Choo P.W., Galil K., Donahue J.G., et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997, 157(11):1217-1224.
8. Schmader K.E., Oxman M.N. Chapter 194. Varicella and Herpes Zoster. Fitzpatrick's Dermatology in General Medicine 2012, McGraw-Hill, New York, Accessed on March 29, 2013. http://www.accessmedicine.com/content.aspx?aID=56088542, L.A. Goldsmith, S.I. Katz, B.A. Gilchrest (Eds.).
9. Ragozzino M.W., Melton L.J., Kurland L.T., et al. Risk of cancer after herpes zoster:a population-based study. NEngl J Med 1982, 307(7):393-397.
10. Buchbinder S.P., Katz M.H., Hessol N.A., et al. Herpes zoster and human immunodeficiency virus infection. JInfect Dis 1992, 166(5):1153-1156.
11. Blank L.J., Polydefkis M.J., Moore R.D., et al. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. JAcquir Immune Defic Syndr 2012, 61(2):203-207.
12. Manuel O., Kumar D., Singer L.G., et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. JHeart Lung Transplant 2008, 27(1):11-16.
13. Gourishankar S., McDermid J.C., Jhangri G.S., et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004, 4(1):108-115.
14. Whitley R.J. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. JInfect Dis 2005, 191(12):1999-2001.
15. Hardy I., Gershon A.A., Steinberg S.P., et al. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. NEngl J Med 1991, 325(22):1545-1550.
16. Jumaan A.O., Yu O., Jackson L.A., et al. Incidence of herpes zoster, before and aftervaricella-vaccination-associated decreases in the incidence of varicella, 1992-2002. JInfect Dis 2005, 191(12):2002-2007.
17. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(Suppl 1):S1-S26.
18. Usatine R.P., Clemente C. Is herpes zoster unilateral?. West J Med 1999, 170(5):263.
19. Sampathkumar P., Drage L.A., Martin D.P. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009, 84(3):274-280.
20. Kost R.G., Straus S.E. Postherpetic neuralgia-pathogenesis, treatment, and prevention. NEngl J Med 1996, 335(1):32-42.
21. Whitley R. Chapter 137 Varicella-Zoster Virus. Principles and Practice of Infectious Diseases, Seventh Edition 2010, 1963-1969. Churchill Livingstone Elsevier, Philadelphia, Accessed on March 29, 2013. Mandell, Douglas, Bennett (Eds.).
22. Goh C.L., Khoo L. Aretrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol 1997, 36(9):667-672.
23. Zerngast W., O'Connor K., Paauw D. Varicella zoster with extended prodrome: a case series. Am J Med 2013, 126(4):359-361.
24. Gilden D.H., Kleinschmidt-DeMasters B.K., LaGuardia J.J., et al. Neurologic complications of the reactivation of varicella-zoster virus. NEngl J Med 2000, 342(9):635-645.
25. Gnann J.W. Varicella-zoster virus: atypical presentations and unusual complications. JInfect Dis 2002, 186(Suppl 1):S91-S98.
26. Yawn B.P., Wollan P.C., Kurland M.J., et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011, 86(2):88-93.
27. Nagasako E.M., Johnson R.W., Griffin D.R., et al. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. JAm Acad Dermatol 2002, 46(6):834-839.
28. Dworkin R.H., Boon R.J., Griffin D.R., et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. JInfect Dis 1998, 178(Suppl 1):S76-S80.
29. Klompas M., Kulldorff M., Vilk Y., et al. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc 2011, 86(12):1146-1153.
30. Oxman M.N., Levin M.J., Johnson G.R., et al. Avaccine to prevent herpes zoster and postherpetic neuralgia in older adults. NEngl J Med 2005, 352(22):2271-2284.
31. Opstelten W., Zaal M.J. Managing ophthalmic herpes zoster in primary care. BMJ 2005, 331(7509):147-151.
32. Lam F.C., Law A., Wykes W. Herpes zoster ophthalmicus. BMJ 2009, 339:b2624.
33. Ormerod L.D., Larkin J.A., Margo C.A., et al. Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS. Clin Infect Dis 1998, 26(1):34-45. [discussion: 46-7].
34. Hellinger W.C., Bolling J.P., Smith T.F., et al. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosissyndrome. Clin Infect Dis 1993, 16(2):208-212.
35. Angles E.M., Nelson S.W., Higgins G.L. Awoman with facial weakness: a classic case of Ramsay Hunt syndrome. JEmerg Med 2013, 44(1):e137-e138.
36. Ibrahimi O.A., Sakamoto G.K., Lee J.J. Acute onset vesicular rash. Herpes zoster. Am Fam Physician 2010, 82(7):815-816.
37. Mehta S.K., Tyring S.K., Gilden D.H., et al. Varicella-zoster virus in the saliva of patientswith herpes zoster. JInfect Dis 2008, 197(5):654-657.
38. Tyring S., Barbarash R.A., Nahlik J.E., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995, 123(2):89-96.
39. Shafran S.D., Tyring S.K., Ashton R., et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. JClin Virol 2004, 29(4):248-253.
40. Tyring S.K., Beutner K.R., Tucker B.A., et al. Antiviral therapy for herpes zoster: randomized,controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000, 9(9):863-869.
41. Beutner K.R., Friedman D.J., Forszpaniak C., et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents Chemother 1995, 39(7):1546-1553.
42. Wood M.J., Johnson R.W., McKendrick M.W., et al. Arandomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. NEngl J Med 1994, 330(13):896-900.
43. Jackson J.L., Gibbons R., Meyer G., et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997, 157(8):909-912.
44. Helgason S., Petursson G., Gudmundsson S., et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000, 321(7264):794-796.
45. Eaglstein W.H., Katz R., Brown J.A. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970, 211(10):1681-1683.
46. Chen N., Yang M., He L., et al. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2010, (12). CD005582.
47. Whitley R.J., Weiss H., Gnann J.W., et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996, 125(5):376-383.
48. Dworkin R.H., Barbano R.L., Tyring S.K., et al. Arandomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009, 142(3):209-217.
49. Kishore-Kumar R., Max M.B., Schafer S.C., et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990, 47(3):305-312.
50. Watson C.P., Evans R.J., Reed K., et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982, 32(6):671-673.
51. Watson C.P., Vernich L., Chipman M., et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998, 51(4):1166-1171.
52. Max M.B., Schafer S.C., Culnane M., et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988, 38(9):1427-1432.
53. Dubinsky R.M., Kabbani H., El-Chami Z., et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004, 63(6):959-965.
54. Moore R.A., Wiffen P.J., Derry S., et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011, (3). CD007938.
55. Gilron I., Bailey J.M., Tu D., et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009, 374(9697):1252-1261.
56. McKeage K., Keam S.J. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging 2009, 26(10):883-892.
57. Ifuku M., Iseki M., Hidaka I., et al. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med 2011, 12(7):1112-1116.
58. Achar A., Chakraborty P.P., Bisai S., et al. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. Acta Dermatovenerol Croat 2012, 20(2):89-94.
59. Achar A., Chatterjee G., Ray T.G., et al. Comparative study of clinical efficacy with amitriptyline, pregabalin, and amitriptyline plus pregabalin combination in postherpetic neuralgia. Indian J Dermatol Venereol Leprol 2010, 76(1):63-65.
60. Watson C.P., Tyler K.L., Bickers D.R., et al. Arandomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993, 15(3):510-526.
61. Irving G.A., Backonja M.M., Dunteman E., et al. Amulticenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011, 12(1):99-109.
62. Backonja M., Wallace M.S., Blonsky E.R., et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008, 7(12):1106-1112.
63. Wolff R.F., Bala M.M., Westwood M., et al. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand 2011, 123(5):295-309.
64. Clere F., Delorme-Morin C., George B., et al. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France. Drugs Aging 2011, 28(9):693-702.
65. Raja S.N., Haythornthwaite J.A., Pappagallo M., et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59(7):1015-1021.
66. Mordarski S., Lysenko L., Gerber H., et al. The effect of treatment with fentanyl patches on pain relief and improvement in overall daily functioning in patients with postherpetic neuralgia. JPhysiol Pharmacol 2009, 60(Suppl 8):31-35.
67. Boureau F., Legallicier P., Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003, 104(1-2):323-331.
68. Meyers J.D. Treatment of herpesvirus infections in the immunocompromised host. Scand J Infect Dis Suppl 1985, 47:128-136.
69. Shepp D.H., Dandliker P.S., Meyers J.D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. NEngl J Med 1986, 314(4):208-212.
70. Arora A., Mendoza N., Brantley J., et al. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. JInfect Dis 2008, 197(9):1289-1295.
71. Ljungman P., Lonnqvist B., Ringden O., et al. Arandomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 1989, 4(6):613-615.
72. Pasternak B., Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010, 304(8):859-866.
73. Shaikh S., Ta C.N. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician 2002, 66(9):1723-1730.
74. Levin M.J., Oxman M.N., Zhang J.H., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. JInfect Dis 2008, 197(6):825-835.
75. Shapiro M., Kvern B., Watson P., et al. Update on herpes zoster vaccination: a family practitioner's guide. Can Fam Physician 2011, 57(10):1127-1131.
76. Schmader K.E., Levin M.J., Gnann J.W., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012, 54(7):922-928.
77. Centers for Disease Control and Prevention. Vaccines and preventable diseases: herpes zoster vaccination for health care professionals. Available at: Accessed October 19, 2012; December 31, 2012. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm.
78. Sanford M., Keating G.M. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010, 27(2):159-176.
79. Schmader K.E., Oxman M.N., Levin M.J., et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012, 55(10):1320-1328.
80. American Colleges of Physicians. American Colleges of Physicians guide to adult immunizations, 4th edition: team-based manual. Available at: Accessed on March 29, 2013. http://immunization.acponline.org/.
81. Merck Canada. Zostavax [package insert]. Kirkland (Quebec). Available at: Accessed December 31, 2012. http://www.merck.ca/assets/en/pdf/products/ZOSTAVAX-PM_E.pdf.
82. Zhang J., Xie F., Delzell E., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012, 308(1):43-49.